Zum Inhalt springen

Riskante Kombinationen von Psychopharmaka bei jungen Patienten

Eine neue Studie zeigt, dass junge Patienten bei der Behandlung mit Psychopharmaka mit besorgniserregender Häufigkeit potenziell gefährliche Kombinationen erhalten. Forscher von Rutgers Health und anderen Institutionen analysierten kürzlich die Krankenversicherungsunterlagen des Staates New York für mehr als 141.000 Patienten, die Psychopharmaka einnahmen. Fast 400 von ihnen hatten mindestens einen Monat oder länger mindestens eine potenziell gefährliche Kombination eingenommen. Ärzte sprechen von schweren Wechselwirkungen zwischen Medikamenten und ihre Anwendung wird in der Regel als „kontraindiziert“ (von der Einnahme abgeraten) angesehen. Der leitende Studienautor Lawrence Kleinman, Professor für Pädiatrie an der Rutgers Robert Wood Johnson Medical School, warnte, dass manche Kinder, deren Krankheit auf herkömmliche Behandlungen nicht anspricht, von der Kombination zwar mehr Nutzen als Risiken haben könnten, „es aber eine gute Praxis erfordert, Patienten und Betreuer über die Risiken und Vorteile zu informieren und ihnen zuzustimmen. Dazu gehört auch, sie darüber… 

Schnelltest zum Nachweis von Dopamin

Forscher der University of Central Florida unter der Leitung von Professor Debashis Chanda vom UCF NanoScience Technology Center haben einen integrierten optischen Sensor entwickelt, der Dopamin direkt in einer unverarbeiteten Blutprobe erkennen kann. Dieser Sensor kann als kostengünstiges und effizientes Screening-Tool für verschiedene neurologische Erkrankungen und Krebsarten dienen und letztlich zu besseren Behandlungsergebnissen für Patienten führen. Die Studie wurde in der Zeitschrift Science Advances veröffentlicht . Der plasmonische Sensor besteht aus einem winzigen Goldmuster, das Elektronen dazu bringt, sich in Wellen gemeinsam zu bewegen. Diese Wellen, Plasmonen genannt, werden durch einen speziellen optischen Aufbau stärker. Wenn ein neues Molekül in die Umgebung des Sensors eintritt, ändert sich die Bewegung der Elektronen, was wiederum die Art und Weise beeinflusst, wie das Licht vom Sensor reflektiert wird. Diese Änderung der Reflexion hilft dabei, die Anwesenheit des Moleküls zu erkennen. Anders als herkömmliche… 

Alzheimer-Test: QIAGEN und Lilly kooperieren

QIAGEN und Lilly kooperieren bei der Entwicklung eines QIAstat-Dx IVD-Panels zur Identifizierung von Patienten mit erhöhtem Risiko für Alzheimererkrankungen. QIAGEN entwickelt erstes QIAstat-Dx IVD-Panel für neurodegenerative Anwendungen // Neues QIAstat-Dx-Panel identifiziert APOE-Genotypen, die als einer von vielen Faktoren eine Rolle bei der Einschätzung des Risikos einer Alzheimererkrankung spielen können // Kooperation sieht Markteinführung des ersten kommerziell erhältlichen IVD-Kits für die APOE-Genotypisierung vor. QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute eine Kooperation mit Eli Lilly and Company zur Unterstützung bei der Entwicklung eines in-vitro-diagnostischen Panels (IVD) für QIAGENs Multiplex-Testplattform QIAstat-Dx zum Nachweis von APOE?Genotypen bekannt gegeben. Diese können eine Rolle bei der Diagnose der Alzheimer-Krankheit spielen. Damit stellt die Zusammenarbeit einen bedeutenden Meilenstein dar: Das QIAstat-Dx-Panel wäre das erste kommerziell erhältliche IVD für die APOE-Genotypisierung. Die Vereinbarung markiert zudem die erste öffentlich bekannt gegebene Kooperation für eine klinische Anwendung… 

Sensei Biotherapeutics to Present Preclinical Data on SNS-103

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical data on SNS-103 will be presented in a poster session at the CRI-ENCI Eighth International Immunotherapy Conference, being held September 8-11, 2024, at the Gaylord National Resort & Convention Center in National Harbor, MD. Presentation Details: CRI-ENCI Eighth International Cancer Immunotherapy ConferenceTitle: Pre-clinical characterization of monoclonal antibodies targeting CD39 activity in the acidic tumor microenvironmentPresenter: F. Donelson Smith, Ph.D., Senior Director, Biologics Discovery & Early DevelopmentPoster Number: 195ADate and time: Sunday, September 8, 2024, 12:05 – 2:05 p.m. EDT

NANOBIOTIX: Two Key Supervisory Board Additions

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering nanoparticle-based therapeutic approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the nominations of Dr. Margaret A. Liu and Ms. Anat Naschitz as observers to its Supervisory Board. Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. The Company’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life

Sotera Health Announces Secondary Offering of Common Stock

Sotera Health Company (Nasdaq: SHC) (the “Company”) today announced the launch of a secondary offering (the “Offering”) of 25,000,000 shares of its common stock, par value $0.01 per share. All 25,000,000 shares are being offered for sale by certain affiliates of Warburg Pincus LLC (“Warburg Pincus”) and GTCR LLC (“GTCR”) as selling stockholders. No other entities, and no individuals, are selling shares in the Offering. It is expected that, as a result of the Offering, the Company’s sponsors (affiliates of Warburg Pincus and GTCR) will cease to own a majority of the Company’s outstanding common stock, which will affect certain sponsor rights and related matters. These rights are described in the Company’s most recently filed annual general meeting proxy statement. The Company is not offering any shares in the Offering and will not receive any of the proceeds from the… 

Brisbane Drug Rehabilitation Centre Launch by Avive Health

Avive Clinic Brisbane, a leading provider of mental health services, is transforming the landscape of drug rehabilitation with its cutting-edge approach to treatment. Addressing the complex challenges of substance use disorders, Avive Clinic Brisbane combines innovative therapies, state-of-the-art facilities, and a patient-centric approach to support individuals on their entire journey to recovery. For more information visit: https://avivehealth.com.au/conditions-we-treat/substance-use-disorders. Substance use disorders are debilitating conditions affecting millions worldwide. They can disrupt every aspect of a person’s life, impacting their physical and mental health, relationships, and overall well-being. Avive Clinic Brisbane recognises the diverse nature of substance use disorders and the need for personalised treatment plans. The clinic’s multidisciplinary team of mental health professionals, including psychiatrists, psychologists, therapists, and addiction specialists, collaborate to design comprehensive programs tailored to each individual’s unique needs. They understand that addiction is a complex issue with no one-size-fits-all… 

Medical Robots Market Report

Medical Robot Market Set to Achieve 12.9% CAGR, Projected to Reach USD 38,701.5 Million by 2034 Due to Advancements in Robot-Assisted Surgery. The global medical robot market is set to witness unprecedented growth over the next decade, with its market size expected to surge from USD 11,502.4 million in 2024 to a staggering USD 38,701.5 million by 2034. This growth trajectory, reflecting a CAGR of 12.9%, is driven by technological advancements, increased demand for minimally invasive surgeries, and the rising adoption of robotics in healthcare. Understanding the Medical Robot Market: The Medical Robot Market encompasses a range of robotic systems and devices designed to assist medical professionals in various tasks, including surgical procedures, rehabilitation, diagnostics, and patient care. These robots offer enhanced precision, reduced recovery times, and the ability to perform complex procedures with minimal human intervention. As the healthcare… 

Class Action Lawsuit Against CrowdStrike

ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 30, 2024 to file lead plaintiff applications in a securities class action lawsuit against CrowdStrike Holdings, Inc. (the “Company”) (NasdaqGS: CRWD), if they purchased the Company’s Class A shares between November 29, 2023 and July 29, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Western District of Texas. Get Help CrowdStrike investors should visit us at https://claimsfiler.com/cases/nasdaq-crwd/ or call toll-free (844) 367-9658. Lawyers at Kahn Swick & Foti, LLC are available to discuss your legal options. About the Lawsuit CrowdStrike and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws. On July 19, 2024, an update pushed by the Company caused global outages for millions of users… 

Class Action Lawsuit Against Moderna

Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Moderna, Inc. (NASDAQ: MRNA) securities between January 18, 2023 and June 25, 2024. Moderna is a biotechnology company that discovers, develops, and commercializes messenger RNA (“mRNA”) therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the U.S., Europe, and internationally. The Allegations: Robbins LLP is Investigating Allegations that Moderna, Inc. (MRNA) Misled Investors Regarding the Efficacy of its RSV Vaccine According to the complaint, the Company’s products include, inter alia, mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (“RSV”) vaccine, intended to protect adults aged 60 years and older from lower respiratory tract disease caused by RSV infection. Plaintiff alleges that during the class period, defendants failed to disclose that:…